公开(公告)号：US20240018245A1

公开(公告)日：2024-01-18

申请号：US18295539

申请日：2023-04-04

Applicant: Genentech, Inc.

Inventor： Bernard Martin FINE ,  Teiko SUMIYOSHI ,  Mengsong LI ,  James Niall COOPER

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K39/395 ,  A61K31/167 ,  A61K31/137

CPC classification number: C07K16/283 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2866 ,  A61K2039/505 ,  A61K39/3955 ,  A61K31/167 ,  A61K31/137 ,  A61K31/573

Abstract: The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20250129162A1

公开(公告)日：2025-04-24

申请号：US18901189

申请日：2024-09-30

Applicant: Genentech, Inc.

Inventor： Bernard Martin FINE ,  Teemu Tapani JUNTTILA ,  Mengsong LI ,  Teiko SUMIYOSHI ,  James Niall COOPER

IPC: C07K16/28 ,  A61K31/138 ,  A61K31/167 ,  A61K31/454 ,  A61K31/573 ,  A61K45/06

Abstract: The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.